Enlivex Therapeutics Ltd.
(NASDAQ : ENLV)

( )
ENLV After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Medical Specialties
symbolcompany%chnglast%shortavg$volume
TMOThermo Fisher Scientific, Inc. 0.25%608.151.0%$814.30m
DHRDanaher Corp. 0.22%324.830.7%$642.68m
ABTAbbott Laboratories 0.47%125.240.8%$554.27m
ISRGIntuitive Surgical, Inc. 1.59%1044.842.3%$526.38m
MDTMedtronic Plc 1.82%130.610.6%$488.66m
ALGNAlign Technology, Inc. 1.47%727.116.3%$358.99m
BDXBecton, Dickinson & Co. -1.26%253.571.0%$357.94m
BAXBaxter International, Inc. -0.36%80.761.8%$321.93m
IDXXIDEXX Laboratories, Inc. 1.66%682.583.8%$315.32m
DXCMDexCom, Inc. 0.41%572.737.8%$296.29m
HRCHill-Rom Holdings, Inc. -0.33%150.352.2%$290.38m
SYKStryker Corp. 1.62%276.041.3%$286.02m
BSXBoston Scientific Corp. 1.63%45.031.0%$260.67m
ZBHZimmer Biomet Holdings, Inc. 3.22%150.391.7%$236.60m
AAgilent Technologies, Inc. 0.10%172.611.6%$234.66m

Company Profile

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company was founded on January 22, 2012 and is headquartered in Nes-Ziona, Israel.